Myles Tang

Myles Tang is a Senior Associate at Altaris, a New York-based private equity firm that invests exclusively in the healthcare industry. He works on the firm's investment team, sourcing, evaluating, and supporting healthcare buyout and growth investments rather than making personal angel checks. Public profiles list his title as Senior Associate (an earlier internal record listed him as Associate), reflecting a progression on the deal team.

Tang earned a Bachelor of Arts in Economics from Amherst College, where he studied from 2013 to 2017. Several profile aggregators also indicate further study in applied economics associated with the University of Oxford. Before Altaris, he worked at the investment bank Lazard, and earlier completed finance-focused internships, including a fixed-income investment internship at JS Cresvale Securities International, an assistant-analyst role at Soochow Securities, and a program-management internship at Standard Chartered Bank.

Altaris itself was founded in 2003 and manages more than $9 billion of equity capital (as of year-end 2023). Since inception the firm has invested in roughly 50 healthcare companies and currently holds a portfolio of around 11 active operating companies. Its stated mission is to build market-leading healthcare businesses that "deliver value to the healthcare system through innovation and efficiency." As a member of the investment team, Tang's work centers on this thesis rather than a separate personal investment program.

*Note: some aggregator sites (e.g., Angels Partners) list small "check sizes" ($100K–$5M) and seed-stage activity for Altaris; these appear to be database artifacts and are inconsistent with the firm's actual control-PE strategy, so they are not treated as reliable here.*

• Invests only in healthcare — across life sciences/pharma, provider and healthcare services, medical devices/products, and non-reimbursement healthcare segments.
• Pursues control and significant-stake transactions (leveraged buyouts, recapitalizations, take-privates) and growth equity, not seed/angel rounds.
• Firm framing: building companies that "deliver value to the healthcare system through innovation and efficiency" while generating returns for investors.
• Operates at private-equity scale (multi-hundred-million to billion-dollar enterprise values), backed by $9B+ in equity capital — meaningfully different from the "seed/angel" label attached to some third-party listings.